Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
Status: | Recruiting |
---|---|
Conditions: | Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/2/2016 |
Contact: | Introgen Therapeutics, Inc. |
Email: | clinicaltrials@introgen.com |
Phone: | 866.631.4646 |
There is a need for more treatment options for patients with recurrent squamous cell cancer
of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that
include disruption of the p53 pathway, a pathway that would ordinarily work to prevent the
development of tumors. In this study the transfer of the p53 gene to tumor cells using a
modified adenovirus (INGN 201) in combination with chemotherapy (cisplatin and fluorouracil)
will be compared to chemotherapy with cisplatin and fluorouracil in patients who have failed
surgery and radiotherapy.
of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that
include disruption of the p53 pathway, a pathway that would ordinarily work to prevent the
development of tumors. In this study the transfer of the p53 gene to tumor cells using a
modified adenovirus (INGN 201) in combination with chemotherapy (cisplatin and fluorouracil)
will be compared to chemotherapy with cisplatin and fluorouracil in patients who have failed
surgery and radiotherapy.
- 18 years or older
- Must have had radiation treatment
- Eligible for chemotherapy
- Not eligible for surgery
We found this trial at
8
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials